USA flag logo/image

An Official Website of the United States Government

Immunoprevention of H. pylori gastritis

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
54186 		Program Year/Program:
2001 / SBIR
Agency Tracking Number:
1R43AI048262-01A1 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. 4134 Business Park Dr Amarillo, TX 79110 0422
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: Immunoprevention of H. pylori gastritis
Agency: HHS
Contract: N/A
Award Amount: $96,284.00
 

Abstract:

DESCRIPTION (provided by applicant): Helicobacter pylori (Hp) gastric infection is a common and serious infectious disease of humans. Current therapeutic regimens, while successful in 80 percent of the instances of infection, are complicated by expense, duration of treatment, emergence of resistant strains of Hp and lack of patient compliance. An ideal alternative to antimicrobial therapy is prophylactic or therapeutic vaccination for Hp. In this phase I SBIR, we will test the hypothesis that proteolytic digests of Hp incorporated into a novel adjuvant formulation will prevent manifestations of bacterial gastritis and promote gastric bacterial clearance in Hp-infected gnotobiotic piglets, an established animal model of this disease. Piglets will be parenterally immunized with Hp digests prior to and after established gastric infection. Evidence for protection (reduced/absent bacterial cfu, local and systemic immunity, etc) will be sought. Protection will be correlated to patterns of Western blot immunoreactivity of convalescent immune sera and isolated leukocyte in vitro responses to putative bacterial antigen(s). Reactive peptides will be isolated by HPLC, sequenced and identified. From these data, the feasibility of parenteral vaccination for Hp will be determined in this nonrodent model of bacterial gastritis and a phase II SBIR will be prepared if the protection data are positive. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Principal Investigator:

Joseph Cummins

Business Contact:


8063761741
JCUMMINS@AMARBIO.COM
Small Business Information at Submission:

AMARILLO BIOSCIENCE, INC.
800 W 9TH AVE AMARILLO, TX 79101

EIN/Tax ID: 751974352
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No